Operation Warp Speed

Operation Warp Speed
Official seal of Operation Warp Speed
Active	May 15, 2020 – February 24, 2021 (285 days)
Disbanded	Transitioned to White House COVID-19 Response Team
Country	United States
Allegiance	United States
Part of	U.S. Department of Defense U.S. Department of Health and Human Services Other various government agencies
Engagements	Coronavirus disease 2019
Website	Coronavirus: Operation Warp Speed
Commanders
Head	Moncef Slaoui
Chief Operating Officer	General Gustave F. Perna
Commander in Chief	Donald Trump Joe Biden

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. ^{[1] [2]} The first news report of Operation Warp Speed was on April 29, 2020, ^{[3] [4] [5]} and the program was officially announced on May 15, 2020. ^[1] It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. ^[6] At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team. ^[7]

The program promoted mass production of multiple vaccines, and different types of vaccine technologies, based on preliminary evidence. Then there were clinical trials. The plan anticipated that some of these vaccines would not prove safe or effective, making the program more costly than typical vaccine development, but potentially leading to the availability of a viable vaccine several months earlier than typical timelines. ^[8]

Operation Warp Speed, initially funded with about $10 billion from the CARES Act (Coronavirus Aid, Relief, and Economic Security) passed by the United States Congress on March 27, 2020, ^[1] was an interagency program that includes components of the Department of Health and Human Services, including the Centers for Disease Control and Prevention, Food and Drug Administration, the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA); the Department of Defense; private firms; and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs. ^[1]

History

President Donald Trump formally announced Operation Warp Speed on May 15, 2020, in the White House Rose Garden.

On May 15, 2020, President Donald Trump officially announced the public-private partnership. ^{[4] [1]} The purpose of Operation Warp Speed was to coordinate Health and Human Services-wide efforts, including the NIH ACTIV ^[9] partnership for vaccine and therapeutic development, the NIH RADx ^[10] initiative for diagnostic development, and work by BARDA. ^[1]

Operation Warp Speed was formed to encourage private and public partnerships to enable faster approval and production of vaccines during the COVID-19 pandemic. ^[2] The name was inspired by terminology for faster-than-light travel used in the Star Trek fictional universe, evoking a sense of rapid progress. ^{[11] [12]}

The Food and Drug Administration announced on June 30, 2020, that a vaccine would need to be at least 50% effective for diminishing the severity of COVID-19 symptoms to obtain regulatory and marketing approval. ^[13]

In January 2021, White House press secretary Jen Psaki announced that the program was expected to undergo a restructure and renaming under the Biden administration. ^{[14] [15]} Also in January 2021, Dr. Moncef Slaoui, former Operation Warp Speed lead, was told not to use the name Operation Warp Speed anymore. ^[16] At the end of February 2021, responsibilities of Operation Warp Speed were transferred into the White House COVID-19 Response Team. ^{[7] [17]}

Goals

According to the Department of Health and Human Services' fact sheet, the main stated goal of Operation Warp Speed was to "produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics". ^[2]

Specific targets, as outlined in various media, include:

• support pharmaceutical companies for R&D of seven different vaccine candidates simultaneously and certain therapeutic compounds ^[2]
• support several vaccine manufacturers for rapid scale-up of manufacturing capacity ^[2]
• support organization and facilitate simultaneous FDA review of Phase I-III clinical trials on several of the most promising vaccine candidates ^[2]
• facilitate manufacturing vaccine candidates while they remain pre-approved during prefinal clinical research to prepare for rapid deployment, if proven to be safe and effective ^{[2] [18]}
• coordinate with the Department of Defense for vaccine supply, production, and deployment around the United States, and track every vaccine vial and the injection schedule for each American receiving a vaccination ^{[2] [19]}

While coordination was expected with the FDA on technical matters, Commissioner Stephen Hahn noted that the FDA would "provide technical and development assistance to Operation Warp Speed, but the manufacturers decide if they're going to go forward or not" and clarified that the agency had "drawn a very bright line at FDA between us and Operation Warp Speed because we're the independent regulator". ^[20]

Budget and leadership

Operation Warp Speed used BARDA as the financial interface between the U.S. federal government and the biomedical industry. ^[21] The program was initially being funded with $10 billion, ^[1] with additional funds allocated through BARDA. ^[1] Funding was increased to about $18 billion by October 2020. ^[22]

Rick Bright, the BARDA director, was reassigned on or about April 22, 2020, following his resistance to (as he phrased it) "efforts to fund potentially dangerous drugs promoted by those with political connections". ^[23] In May, new leadership was announced. Moncef Slaoui was named Operation Warp Speed's chief adviser. ^[1] Slaoui is a vaccine researcher and, formerly, Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline, where he led the development of five vaccines. ^[1] General Gustave F. Perna, who served as commanding general of Army Materiel Command, was named Operation Warp Speed chief operating officer. ^{[1] [24]} Retired Lieutenant General Paul A. Ostrowski, who previously served as director of the Army Acquisition Corps, was the director of supply, production and distribution. ^{[25] [26]} Army Major General Christopher J. Sharpsten was the deputy director. ^{[27] [28]}

Alex Azar, Mark Esper, Jared Kushner and Adam Boehler were on the board of directors of OWS, while Deborah Birx, Tony Fauci, Francis Collins, and Robert Redfield were nonvoting advisers. ^{[29] [30]}

Companies receiving research funding

See also: COVID-19 vaccine clinical research § Trial and authorization status

As of August 2020, eight companies were chosen for funding of some $11 billion to expedite development and preparation for manufacturing their respective vaccine candidates. ^{[31] [32]}

The vaccine developers, different vaccine technologies, and treatments receiving government research funding were:

Name	Technology	Amount	Date announced	Vaccine candidate	Date FDA authorized	Notes
Johnson & Johnson (Janssen Pharmaceutical) [33] [34] [35]	Non-replicating viral vector	$1 billion	August 5, 2020	Ad26.COV2-S	February 28, 2021	This funding is in addition to $456 million the government awarded in March 2020. [36] [37] FDA authorized emergency use only. [38]
AstraZeneca–University of Oxford [39] and Vaccitech [40]	Modified chimpanzee adenovirus viral vector	$1.2 billion	May 21, 2020	AZD1222	No FDA authorization.	First authorized December 20, 2020, in the United Kingdom. [41] In March 2021, a number of countries paused use of the vaccine out of fears it may be implicated in cases of blood clotting observed in vaccine recipients. [42]
Moderna [31] [32]	mRNA	$1.53 billion	August 11, 2020	mRNA-1273	December 18, 2020	The government had already given Moderna two grants of $483 million and $472 million. [43] The $1.53 billion announced on August 11 brought the total investment to $2.48 billion. FDA authorized emergency use only. [44]
Novavax [45] [46] [47]	SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant	$1.6 billion for advance commercial-scale manufacturing	July 7, 2020	NVX‑CoV2373		Funding to demonstrate commercial-scale manufacturing; federal government will own the 100 million doses produced, but will be made available for clinical trials
Merck and IAVI	Antiviral drug research and immune response therapy [48]	$38 million	April 15, 2020			two vaccine projects terminated by Merck, January 25, 2021 [48]
Sanofi and GlaxoSmithKline [49]	Protein (insect cell lines) with adjuvant	$2.1 billion	July 31, 2020	VAT00008		On December 11, 2020, the companies announced that they would delay the vaccine's release until late 2021 because it produced "insufficient immune response" in elderly people. [50]

Indirectly funded companies include:

• Inovio ^{[51] [52]}

As of October 2020, Operation Warp Speed had spent less than $1 billion to support the development and manufacturing of three monoclonal antibody treatments, versus almost $10 billion on six vaccines. ^[53]

• Regeneron was to receive $450 million to develop and supply a monoclonal antibody drug, according to a government announcement on July 7, 2020. ^[54]

Pfizer–BioNTech

The BioNtech project to develop a novel mRNA technology for a COVID-19 vaccine was called "Project Lightspeed", which started in mid-January 2020 at BioNTech's laboratories in Mainz, Germany, just days after the SARS-Cov-2 genetic sequence was first made public. ^[55] In September 2020, BioNTech received €375 million (US$445 million) from the government of Germany to accelerate the development and production capacity of the Pfizer–BioNTech COVID-19 vaccine. ^{[56] [57] [58]} On November 9, the Pfizer–BioNTech partnership announced positive early results from its Phase III trial of the BNT162b2 vaccine candidate, and on December 11, the FDA provided emergency use authorization, initiating the distribution of the vaccine. ^[59] Pfizer CEO Albert Bourla said that the company had not taken Warp Speed funding for the development of the vaccine out of a desire "to liberate our scientists [from] any bureaucracy that comes with having to give reports and agree how we are going to spend the money in parallel or together". ^[60]

On July 22, 2020, the U.S. government placed a conditional advance-purchase order of $2 billion with Pfizer to manufacture 100 million doses of a COVID-19 vaccine, with an option for 500 million more, for use in the United States if the vaccine was shown to be safe, effective, licensed, and authorized by the Food and Drug Administration (FDA). ^{[57] [61] [62] [63]} On December 23, 2020, the Trump administration announced that they had ordered another 100 million doses from Pfizer. ^[64]

After Pfizer-BioNTech's November 9 announcement, Vice President Mike Pence wrote in a tweet that credit belonged to the "public-private partnership forged by" Trump. Pfizer's head of vaccine and research and development, Kathrin Jansen, had said on November 8 that they "were never part of the Warp Speed"; a day later, a company spokeswoman said that the company was "part of Operation Warp Speed as a supplier of a potential coronavirus vaccine". ^{[65] [66] [67]} Experts disagreed whether the U.S. government's conditional advance order "played an important role in expediting Pfizer’s vaccine development process". ^{[57] [61]}

The United Kingdom was the first country to authorize the vaccine on an emergency basis on December 2, 2020. ^[68] Emergency use authorization in the United States was issued December 11, 2020. ^[69]

Distribution

Vaccine doses purchased by Operation Warp Speed were sent from manufacturers via UPS and FedEx to locations specified by state governments.^{[ citation needed ]} The Federal Pharmacy Partnership delivers doses to CVS and Walgreens locations, which then send pharmacists for mass vaccinations at care facilities like nursing homes.^{[ citation needed ]}

In October 2020, Alex Azar, at that time the United States Secretary of Health and Human Services, predicted a hundred million available doses by the end of the year. ^[70] The Trump administration later reduced the goal to twenty million doses. As of January 6, 2021, the CDC was reporting 17,288,950 doses distributed, but only 5,306,797 actually administered to a person. ^[71] Of those, 3,416,875 were distributed and 511,635 administered through the Federal Pharmacy Partnership. General Gustave Perna said reporting delays cause the administration numbers to lag by 72 to 96 hours. ^[72] By January 31, 2021, when Operation Warp Speed was being transferred to the Biden Administration, 63.7 million doses had been delivered of a total of 200 million doses that Pfizer and Moderna were contracted to provide by the end of March 2021. ^[73]

The distribution effort was criticized for lack of coordination between federal and state governments, ^[74] and lack of timely federal funding for mass vaccination campaigns. ^[70] Other reasons cited included the Christmas holiday, employees declining to be vaccinated, a longer than typical time spent on paperwork or answering patient questions, the required observation time, and shortage of trained staff. ^[75]

Reception

See also: COVID-19 vaccine § Society and culture

Cost

Although initially budgeted by Congress for about $10 billion in May 2020, ^[1] Operation Warp Speed had spent $12.4 billion by mid-December on vaccine developers for the combined costs of R&D and pre-approval manufacturing for millions of vaccine doses. ^[76]

Operation Warp Speed anticipated that some of these vaccines would not prove safe or effective, making the program more costly than typical vaccine development, but potentially leading to the availability of a viable vaccine several months earlier than typical timelines. ^[8] Government subsidies allowed the COVID-19 vaccines to be distributed with initial pricing similar to that of the annual influenza vaccine. ^[77]

Timeline

The goals of the project –to develop, manufacture, and distribute hundreds of millions of COVID-19 vaccine doses by the end of 2020 –were initially criticized as being unrealistic, based on decades of experience in developing viral infection vaccines which normally require years or decades for assuring the chosen vaccine will not be toxic and have adequate efficacy. ^{[5] [78] [79]}

Most viral infections do not have vaccines because the vaccine technology failed in early-stage clinical trials. ^{[5] [78]} Because many vaccines cause side effects, such as pain at the injection site, headaches, and influenza symptoms, safety testing requires years^{[ citation needed ]} of observation in thousands of clinical trial participants. ^{[78] [79]} Similarly, sufficient time –a year or multiple years –is usually needed to be certain a vaccine has durable efficacy while the virus remains pandemic. ^{[24] [78] [79]} Despite extensive previous research attempts to produce safe, effective vaccines against coronaviruses, such as SARS and MERS, all vaccine candidates for coronavirus infections have failed during clinical research, and no vaccine existed to prevent any coronavirus infection. ^[78] To prepare for manufacturing and distribution, Operation Warp Speed expended resources and financing before the safety and efficacy results of vaccine candidates were known.

In the case of Operation Warp Speed, effective vaccines made by BioNTech in Germany and Pfizer and Moderna were given an emergency use authorization by the FDA in December 2020, established an exceptionally fast development and approval timeline for vaccines granted emergency marketing.^{[ failed verification ]} Pfizer joined the Warp Speed program in July 2020,^{[ failed verification ]} and signed a $1.95 billion contract to be paid out when the vaccine would be FDA approved, and included an initial order of 100 million vaccines. ^[80] In December 2020, the Trump administration ordered 200 million additional vaccines from Pfizer. ^[81]

Conclusion

At the end of February 2021, Operation Warp Speed transitioned into the White House COVID-19 Response Team under the Biden Administration. ^{[7] [15]}

Competition

There was potential that the Warp Speed project would expend effort and funding in direct competition with publicly traded American vaccine companies already fully engaged and financed for development. ^[5] There was also the possibility that a billion dollars or more of U.S. taxpayer money would be expended on only American efforts or a narrow alternate choice, such as investing in one other vaccine platform –the University of Oxford-AstraZeneca candidate for which the U.S. already paid US$1 billion in May 2020 to receive 300 million doses for American use, when the AstraZeneca vaccine was successful in advancing to proof of safety and efficacy beyond its status as an early-stage Phase I–II trial in May. ^[82]

Warp Speed did not partner with Chinese vaccine development organizations, or with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations, or the European Commission, which are coordinating and financing international programs for multiple vaccine development, having raised $8 billion together from international partners on May 4 for a Coronavirus Global Response. ^[4] The U.S. government chose not to include Operation Warp Speed as part of the international Solidarity trial on vaccine development, organized by the WHO. ^[4]

President Trump displays Executive Order 13962, which requires priority access to COVID-19 vaccines developed in the United States, signed December 8, 2020

On December 8, 2020, President Trump signed an executive order mandating that companies sell vaccine to the US before selling to any other countries (even if they already had contracts with other countries). ^{[83] [84]}

Concern for equitable access

The focus of Operation Warp Speed to deploy approved COVID-19 vaccines first for the American people raised ethical and logistical concerns that access to vaccines outside of the United States may be restricted during 2021, leaving low-to-middle-income countries with no or minimal supply. ^[85] Concerns were elevated when the Trump administration withdrew its financial support for the WHO and COVAX, and whether the program would participate in international vaccination practices, optimization, and education against vaccine hesitancy and misinformation. ^[85] In February 2021 after Operation Warp Speed was transitioned to the White House COVID-19 Response Team, the United States pledged to donate any vaccine surplus out of concern for vaccine-poor regions, such as Africa. ^[86]

Vaccine hesitancy

Main article: COVID-19 vaccine misinformation and hesitancy

There was concern that the name and intended shortened timeline of Operation Warp Speed could encourage vaccine hesitancy, with one expert stating that "some of the language coming out of the White House is very damaging" because one argument of anti-vaccinators is that products are rushed to market without adequate testing. ^[4] Failure of the public to have confidence in a new vaccine and refuse vaccination is a global health concern, ^[87] which increases the risk of further viral spreading that could lead to ongoing COVID-19 outbreaks during 2020–21. ^[88] A September 2020 survey found that half of American adults surveyed said they would not accept a vaccination if it was available at that time, and three-quarters expressed concerns about the pace of the process and fears that a vaccine might be confirmed before its safety and effectiveness are fully understood. ^[89]

Leader neutrality

The leader of the Operation Warp Speed project, Moncef Slaoui, had been a board member of the U.S. vaccine developer, Moderna, and divested his shares in Moderna stock, at a potential personal gain of $10 million, raising questions of his neutrality in judging vaccine candidates. ^[90] Although Slaoui resigned from the Moderna board when named to head Warp Speed, his share value in Moderna stock increased by $3 million in one day when Moderna announced an advance in vaccine clinical research. ^[90] At the request of the incoming Biden administration, Slaoui resigned from the project in early January 2021. ^[91]

Lawsuits and insider trading

Shareholders sued biotech firm Inovio, claiming the company misled the public when it reported how quickly it had designed the blueprint for its vaccine candidate. ^[92] A class action lawsuit was filed in August 2020 against Vaxart in Northern California U.S. District Court for alleged securities fraud, ^[93] a concern related to Vaxart executives enriching themselves by selling shares timed to positive news on vaccine development during mid-2020. ^[94] Executives, board members, and investment firms holding shares in vaccine and therapeutic companies, including Moderna, Novavax, and Regeneron, took profits worth some US$1 billion (about €830 million) on positive news during 2020. ^[94]

References

1. "Trump Administration Announces Framework and Leadership for 'Operation Warp Speed'". U.S. Department of Health and Human Services. May 15, 2020. Archived from the original on December 16, 2020. Retrieved May 15, 2020. Among its other objectives, Operation Warp Speed aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021.
2. "Fact Sheet: Explaining Operation Warp Speed". US Department of Health and Human Services. November 10, 2020. Archived from the original on December 19, 2020. Retrieved November 24, 2020.
3. Jacobs, Jennifer; Armstrong, Drew (April 29, 2020). "Trump's 'Operation Warp Speed' aims to rush coronavirus vaccine". Bloomberg News. Archived from the original on December 17, 2020. Retrieved May 15, 2020.
4. Cohen, Jon (May 12, 2020). "Unveiling 'Warp Speed,' the White House's America-first push for a coronavirus vaccine". Science . doi:10.1126/science.abc7056. S2CID   219432336. Archived from the original on November 29, 2020. Retrieved May 16, 2020.
5. Sanger, David E. (April 29, 2020). "Trump seeks push to speed vaccine, despite safety concerns". The New York Times. Archived from the original on December 9, 2020. Retrieved May 15, 2020.
6. Kaplan, Sheila (January 15, 2021). "Biden Picks Former F.D.A. Chief to Lead Federal Vaccine Efforts". The New York Times . Archived from the original on January 15, 2021. Retrieved January 15, 2021.
7. Zraick, Karen (February 24, 2021). "Meet the key members of Biden's Covid-19 response team". The New York Times. ISSN   0362-4331 . Retrieved March 7, 2021.
8. Jacobs, Jennifer; Armstrong, Drew (April 29, 2020). "Trump's 'Operation Warp Speed' Aims to Rush Coronavirus Vaccine". Bloomberg News. Archived from the original on December 17, 2020. Retrieved May 15, 2020.
9. ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)
10. RAPID ACCELERATION OF DIAGNOSTICS (RADX)
11. LaFraniere, Sharon; Thomas, Katie; Weiland, Noah; Baker, Peter; Karni, Annie (August 2, 2020). "Scientists Worry About Political Influence Over Coronavirus Vaccine Project". The New York Times. Archived from the original on December 19, 2020. Retrieved December 17, 2020.
12. McGinley, Laurie (August 11, 2020). "Meet the most important federal official you probably don't know – the man who holds the fate of the coronavirus vaccine in his hands". The Washington Post. Archived from the original on December 14, 2020. Retrieved December 17, 2020.
13. Elizabeth Weise (June 30, 2020). "FDA says a coronavirus vaccine would have to be at least 50% effective to be approved". USA Today. Archived from the original on December 12, 2020. Retrieved July 1, 2020.
14. Kennedy, Merrit (January 15, 2021). "Biden Administration Will Rename 'Operation Warp Speed,' Citing Trump 'Failures'". NPR . Archived from the original on January 29, 2021. Retrieved January 29, 2021.
15. Kaplan, Sheila; Stolberg, Sheryl Gay (January 15, 2021). "Biden picks a former F.D.A. chief to lead federal vaccine efforts, which will drop the name Operation Warp Speed". The New York Times. ISSN   0362-4331. Archived from the original on January 27, 2021. Retrieved January 29, 2021.
16. Cohen, Jon (January 29, 2021). "Ex-vaccine chief reflects on triumphs, failures, and Trump". Science. 371 (6528): 449–450. Bibcode:2021Sci...371..449C. doi: 10.1126/science.371.6528.449 . PMID   33510005.
17. Vergun, David (February 25, 2021). "DOD Officials Provide COVID-19 Response Update". U.S. Department of Defense. Retrieved March 7, 2021.
18. David Wallace-Wells (December 7, 2020). "We had the vaccine the whole time". Intelligencer, New York Magazine, Vox Media Network, Inc. Archived from the original on December 8, 2020. Retrieved December 8, 2020.
19. C. Todd Lopez (October 28, 2020). "In Warp Speed Effort, Knowing Where Vaccines Are Is Key to Distribution Strategy". US Department of Defense. Archived from the original on December 5, 2020. Retrieved December 8, 2020.
20. "AMA, FDA video update: The critical role of health care professionals during COVID-19". AMA-Assn.org. American Medical Association. August 14, 2020. Archived from the original on December 18, 2020. Retrieved December 17, 2020.
21. Dan Gorenstein (October 30, 2014). "BARDA: The venture capital firm buried in the US government". Marketplace, Minnesota Public Radio. Archived from the original on June 13, 2020. Retrieved November 24, 2020.
22. Stephanie Baker; Cynthia Koons (October 29, 2020). "Inside Operation Warp Speed's $18 Billion Sprint for a Vaccine". Bloomberg Businessweek. Archived from the original on December 8, 2020. Retrieved November 24, 2020.
23. Collins, Kaitlan; Diamond, Jeremy; Klein, Betsy (April 22, 2020). "Director of key federal vaccine agency says his departure was retaliation". CNN. Archived from the original on November 1, 2020. Retrieved August 30, 2020.
24. Crisp, Elizabeth (May 15, 2020). "Trump launches 'operation warp speed' effort to develop coronavirus vaccine by year's end". Newsweek. Archived from the original on May 19, 2020. Retrieved May 15, 2020. The project will cost billions of dollars, one of the people said. And it will almost certainly result in significant waste by making inoculations at scale before knowing if they'll be safe and effective –meaning that vaccines that fail will be useless. But it could mean having doses of vaccine available for the American public by the end of this year, instead of by next summer.
25. Guckert, Ross (June 4, 2020). "PEO Perspective: June 2020". PEO EIS. Archived from the original on December 20, 2020. Retrieved December 8, 2020.
26. "LTG Paul Ostrowski, USA (Ret)". National Defense Industrial Association. Archived from the original on December 20, 2020. Retrieved November 27, 2020.
27. Thorn, Amy. "Operation Warp Speed Raises Many Questions from The Supply Chain Industry Some with Answers That Have Yet to Emerge". DigiTech Insight. Retrieved July 21, 2021.
28. "Operation Warp Speed Leader Joins ISOA for an Online Discussion on the COVID-19 Vaccine" (Press release). International Stability Operations Association. December 11, 2020. Retrieved July 21, 2021.
29. Borrell, Brendan Jonathan (2021). The first shots: the epic rivalries and heroic science behind the race to the coronavirus vaccine. New York. pp. 139–143. ISBN   978-0-358-56984-8. OCLC   1275436164.
30. "Inside the Messy Race to Develop a COVID Vaccine". esquire.com. October 19, 2021. Retrieved November 14, 2023.
31. Slaoui, Moncef; Hepburn, Matthew (August 26, 2020). "Developing safe and effective covid vaccines – Operation Warp Speed's strategy and approach". New England Journal of Medicine. 383 (18): 1701–1703. doi: 10.1056/nejmp2027405 . ISSN   0028-4793. PMID   32846056. S2CID   221347918. advancing eight vaccines in parallel will increase the chances of delivering 300 million doses in the first half of 2021 ... Of the eight vaccines in OWS's portfolio, six have been announced and partnerships executed with the companies: Moderna and Pfizer/BioNTech (both mRNA), AstraZeneca and Janssen (both replication-defective live-vector), and Novavax and Sanofi/GSK (both recombinant-subunit-adjuvanted protein). These candidates progressed to clinical trials.
32. Noah Higgins-Dunn (August 14, 2020). "The U.S. has already invested billions in potential coronavirus vaccines. Here's where the deals stand". CNBC. Archived from the original on December 8, 2020. Retrieved September 24, 2020.
33. Rivers, Brenda Marie (August 6, 2020). "Johnson & Johnson Secures $1B in Federal Vaccine Production Funding". GovCon Wire. Archived from the original on October 27, 2020. Retrieved November 19, 2020.
34. "HHS, DOD Collaborate With Johnson & Johnson to Produce Millions of COVID-19 Investigational Vaccine Doses". August 5, 2020. Archived from the original on December 12, 2020. Retrieved November 19, 2020.
35. Higgins-Dunn, Noah (August 5, 2020). "Johnson & Johnson reaches deal with U.S. for 100 million doses of coronavirus vaccine at more than $1 billion". CNBC. Archived from the original on December 9, 2020. Retrieved November 19, 2020.
36. "Experimental Johnson & Johnson vaccine protects monkeys in a single dose, study finds". CNBC. Reuters. July 30, 2020. Archived from the original on October 25, 2020. Retrieved November 19, 2020.
37. Erman, Michael (August 7, 2020). "U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate". Reuters. Archived from the original on December 12, 2020. Retrieved November 19, 2020.
38. "Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory Committee on Immunization Practices' Recommendation to Use Janssen's COVID-19 Vaccine in People 18 and Older". Centers for Disease Control and Prevention (CDC) (Press release). February 28, 2021. Retrieved March 24, 2021.
39. "Trump Administration's Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October". HHS.gov (Press release). May 21, 2020. Archived from the original on December 20, 2020. Retrieved July 22, 2020.
40. "Vaxart oral COVID-19 vaccine joins Trump's 'Warp Speed,' ramps up manufacturing capacity". Genetic Engineering and Biotechnology News. June 29, 2020. Archived from the original on September 29, 2020. Retrieved July 1, 2020.
41. "Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK". BBC News Online. December 30, 2020. Retrieved March 24, 2020.
42. Sam Meredith (March 15, 2021). "Germany, France, Spain and Italy become latest countries to suspend AstraZeneca vaccine over blood clot fears". CNBC. Retrieved March 24, 2020.
43. Adams, Ben (July 27, 2020). "Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test". FierceBiotech. Archived from the original on December 9, 2020. Retrieved November 20, 2020.
44. "Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine". US National Institutes of Health. December 18, 2020. Retrieved March 24, 2020.
45. Katie Thomas (July 7, 2020). "U.S. Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine". The New York Times. Archived from the original on December 17, 2020. Retrieved July 7, 2020.
46. "HHS, DOD Collaborate with Novavax to Produce Millions of COVID-19 Investigational Vaccine Doses in Commercial-Scale Manufacturing Demonstration Projects". HHS.gov (Press release). July 6, 2020. Archived from the original on December 21, 2020. Retrieved December 20, 2020.
47. "Novavax Announces $1.6 Billion Funding from Operation Warp Speed". Novavax. July 7, 2020. Archived from the original on December 17, 2020. Retrieved December 20, 2020.
48. Matthew Herper; Helen Branswell (January 26, 2021). "In a major setback, Merck to stop developing its two Covid-19 vaccines and focus on therapies". STAT. Archived from the original on February 6, 2021. Retrieved February 5, 2021.
49. Angus Liu (July 31, 2020). "Top vaccine players Sanofi, GSK win $2.1B Warp Speed funding for COVID-19 shot". FiercePharma. Archived from the original on November 28, 2020. Retrieved September 24, 2020.
50. Hollingsworth, Julia (December 11, 2020). "GlaxoSmithKline and Sanofi Pasteur vaccine delayed until late 2021". CNN. Archived from the original on December 11, 2020. Retrieved December 11, 2020.
51. "INOVIO Reports Positive Interim Phase I Data for COVID-19 DNA Vaccine, Joins 'Warp Speed' Primate Study". Genetic Engineering and Biotechnology News. June 30, 2020. Archived from the original on October 1, 2020. Retrieved July 1, 2020.
52. Gelles, David; Murphy, Heather (August 11, 2020). "This Company Boasted to Trump About Its Covid-19 Vaccine. Experts Are Skeptical". The New York Times. ISSN   0362-4331. Archived from the original on November 25, 2020. Retrieved September 25, 2020. And while the company has said that it is part of Operation Warp Speed –the flagship federal effort to quickly produce treatments and vaccines for the coronavirus –Inovio is not on the list of companies selected to receive financial support to mass-produce vaccines.
53. Brennan, Zachary (October 2, 2020). "Warp Speed's focus on vaccines may have shortchanged antibody treatments". Politico. Archived from the original on December 8, 2020. Retrieved October 8, 2020.
54. "HHS, DOD Collaborate with Regeneron on Large-Scale Manufacturing Demonstration Project of COVID-19 Investigational Therapeutic Treatment". HHS.gov (Press release). July 7, 2020. Archived from the original on December 18, 2020. Retrieved October 8, 2020.
55. "Aiming to address the global coronavirus pandemic: Project Lightspeed". BioNTech. 2020. Archived from the original on December 18, 2020. Retrieved December 13, 2020.
56. "BioNTech wins $445 million German grant for COVID-19 vaccine". Reuters. September 15, 2020. Archived from the original on January 25, 2021. Retrieved January 7, 2021.
57. Griffin, Riley; Armstrong, Drew (November 9, 2020). "Pfizer Vaccine's Funding Came From Berlin, Not Washington". Bloomberg News . Archived from the original on November 9, 2020. Retrieved February 8, 2024.
58. "BioNTech erhält BMBF-Förderung von bis zu 375 Millionen Euro für COVID-19-Impfstoffprogramm BNT162" [BioNTech receives BMBF funding of up to 375 million euros for COVID-19 vaccine program BNT162]. investors.biontech.de (in German). September 15, 2020. Retrieved August 30, 2021.
59. Maxouris, Christina (December 12, 2020). "FDA's Covid-19 vaccine authorization is a 'monumental moment,' expert says. It came on the deadliest day of the pandemic". CNN . Archived from the original on December 17, 2020. Retrieved December 12, 2020.
60. Axios (November 9, 2020). "Pfizer CEO says he would've released vaccine data before election if possible". Axios. Archived from the original on December 10, 2020. Retrieved November 11, 2020.
61. Dale, Daniel (November 10, 2020). "Fact-checking the battle for credit over Pfizer's vaccine announcement". CNN . Archived from the original on November 16, 2020. Retrieved February 8, 2024.
62. Alexander Nazaryan (November 9, 2020). "So is Pfizer part of Operation Warp Speed or not? Yes and no". Yahoo Financial News. Archived from the original on December 11, 2020. Retrieved November 9, 2020.
63. "U.S. Government Engages Pfizer to Produce Millions of Doses of COVID-19 Vaccine". US Department of Health and Human Services. July 22, 2020. Archived from the original on December 17, 2020. Retrieved July 23, 2020.
64. Gumbrecht, Jamie; Holmes, Kristen (December 23, 2020). "Trump administration to purchase additional 100 million Pfizer vaccine doses". CNN . Retrieved February 8, 2024.
65. Katie Thomas; David Gelles; Carl Zimmer (November 9, 2020). "Pfizer's early data shows vaccine is more than 90% effective". The New York Times. Archived from the original on December 18, 2020. Retrieved November 9, 2020. On Monday, a spokeswoman for Pfizer clarified that the company is part of Operation Warp Speed as a supplier of a potential coronavirus vaccine
66. "Was the Pfizer vaccine part of the government's Operation Warp Speed?". The New York Times. November 10, 2020. Archived from the original on December 16, 2020. Retrieved November 14, 2020.
67. Czachor, Emily (November 9, 2020). "Pfizer Avoided R&D Funding From Trump's Operation Warp Speed Because of Bureaucracy, Politics". Newsweek. Archived from the original on December 9, 2020. Retrieved November 9, 2020.
68. "U.K. becomes first country to approve Pfizer-BioNTech Covid-19 vaccine". NBC News . December 2, 2020. Retrieved March 24, 2021.
69. "Pfizer-BioNTech COVID-19 Vaccine". US Food & Drug Administration (Press release). February 28, 2021. Retrieved March 24, 2021.
70. "Trump misses 20 million Covid shot target". Politico . December 30, 2020. Archived from the original on January 4, 2021. Retrieved January 7, 2021.
71. "CDC COVID Data Tracker". March 28, 2020. Archived from the original on January 25, 2021. Retrieved January 6, 2021.
72. "Operation Warp Speed chief says Covid vaccine distribution 'should be better' as U.S. misses goal". CNBC . December 30, 2020. Archived from the original on January 4, 2021. Retrieved January 7, 2021.
73. "Operation Warp Speed: Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges". US Government Accountability Office. February 11, 2021. Retrieved May 6, 2022.
74. "Baker Says More Communication From Feds Is Key To Smooth Vaccine Distribution". January 5, 2021. Archived from the original on February 14, 2021. Retrieved January 7, 2021.
75. "Pace Of Coronavirus Vaccination Lags Supply In Mass". January 4, 2021. Archived from the original on January 7, 2021. Retrieved January 7, 2021.
76. Emily Barone (December 14, 2020). "The Trump Administration's 'Operation Warp Speed' Has Spent $12.4 Billion on Vaccines. How Much Is That, Really?". Time Magazine. Archived from the original on January 25, 2021. Retrieved January 30, 2021.
77. Jennings, Katie (November 17, 2020). "How Much Will A Covid-19 Vaccine Cost?". Forbes. Archived from the original on December 13, 2020. Retrieved December 6, 2020.
78. Diamond, Michael S; Pierson, Theodore C (May 13, 2020). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC   7219397 . PMID   32407708.
79. Nisen, Max (April 30, 2020). "Operation Warp Speed needs to waste money on vaccines". Bloomberg News. The Washington Post. Archived from the original on June 11, 2020. Retrieved May 28, 2020.
80. Lovelace, Berkeley Jr. (November 18, 2020). "Watch live: U.S. officials speak on Operation Warp Speed after Pfizer releases positive vaccine data". CNBC. Retrieved July 1, 2021.
81. "Fact-check: Did Trump not contract for enough vaccines to cover the U.S. population?". www.msn.com. Retrieved July 1, 2021.
82. McKeever, Vicky (May 21, 2020). "AstraZeneca receives $1 billion in U.S. funding for Oxford University coronavirus vaccine". CNBC. Archived from the original on May 28, 2020. Retrieved May 28, 2020.
83. Christensen, Jen; Acosta, Jim; Carvajal, Nikki; Vazquez, Maegan (December 8, 2020). "Trump to sign order aimed at prioritizing Covid-19 vaccine shipment to Americans". CNN. Archived from the original on December 8, 2020. Retrieved December 8, 2020.
84. Trump, Donald. "Executive Order on Ensuring Access to United States Government COVID-19 Vaccines". whitehouse.gov . Archived from the original on January 20, 2021. Retrieved December 12, 2020– via National Archives.
85. Kim, Jerome H; Hotez, Peter; Batista, Carolina; Ergonul, Onder; Figueroa, J Peter; Gilbert, Sarah; Gursel, Mayda; Hassanain, Mazen; Kang, Gagandeep; Lall, Bhavna; Larson, Heidi; Naniche, Denise; Sheahan, Timothy; Shoham, Shmuel; Wilder-Smith, Annelies; Strub-Wourgaft, Nathalie; Yadav, Prashant; Bottazzi, Maria Elena (March 26, 2021). "Operation Warp Speed: implications for global vaccine security". The Lancet Global Health. 9 (7): e1017–e1021. doi: 10.1016/S2214-109X(21)00140-6 . ISSN   2214-109X. PMC   7997645 . PMID   33780663.
86. Carl O'Donnell; Andrea Shalal (February 18, 2021). "Biden to pledge $4 billion to COVAX vaccine program at G7 meeting Friday". Reuters. Retrieved April 1, 2021.
87. "Ten health issues WHO will tackle this year". World Health Organization. 2019. Archived from the original on November 11, 2019. Retrieved May 26, 2020.
88. Dubé, Eve; Laberge, Caroline; Guay, Maryse; Bramadat, Paul; Roy, Réal; Bettinger, Julie (August 1, 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–1773. doi:10.4161/hv.24657. ISSN   2164-554X. PMC   3906279 . PMID   23584253.
89. "U.S. Public Now Divided Over Whether To Get COVID-19 Vaccine". Pew Research. September 17, 2020. Archived from the original on October 15, 2020. Retrieved October 15, 2020.
90. Alaric Dearment (May 19, 2020). "Head of Trump's Covid-19 vaccine program to divest more than $10M in Moderna shares after criticism". MedCity News. Retrieved May 28, 2020.
91. Kristen Holmes; Sarah Mucha; Gregory Lemos (January 13, 2021). "Head of US vaccine effort resigns at request of incoming Biden administration but will stay through transition". CNN . Archived from the original on February 1, 2021. Retrieved January 30, 2021.
92. Gelles, David; Murphy, Heather (August 11, 2020). "This Company Boasted to Trump About Its Covid-19 Vaccine. Experts Are Skeptical". The New York Times. ISSN   0362-4331. Archived from the original on November 25, 2020. Retrieved September 25, 2020.
93. Himmelberg v. Vaxart, Inc. Archived October 11, 2020, at the Wayback Machine , No. 20-cv-05949 (N.D. Cal. August 24, 2020)
94. Gelles, David; Drucker, Jesse (July 25, 2020). "Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine". The New York Times. ISSN   0362-4331. Archived from the original on September 24, 2020. Retrieved September 25, 2020.

Further reading

• Brendan Borrell (2021). The First Shots: The Epic Rivalries and Heroic Science Behind the Race to the Coronavirus Vaccine. Mariner Books. ISBN   978-0-358-56984-8.